[{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Biotech","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"$3.0 million","newsHeadline":"Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Neumentum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumentum to Present New Data for Drug Candidate NTM-001 at the 2020 ASHP Midyear Clinical Meeting and Exhibition","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$125.0 million","newsHeadline":"Omeros Announces Agreement to Sell OMIDRIA\u00ae Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Evolution Research Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Nemera","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nemera\u2019s Preservative-Free Multi-Dose Eyedropper Approved in Brazil for Ach\u00e9\u2019s NSAID\u2019s and Dry Eye Formulations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare Acquisitions","pharmaFlowCategory":"D","amount":"$188.4 million","upfrontCash":"Undisclosed","newsHeadline":"Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","amount":"$1,326 million","upfrontCash":"$126.0 million","newsHeadline":"Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","amount":"$1,325 million","upfrontCash":"$125.0 million","newsHeadline":"Omeros Announces Agreement to Sell OMIDRIA\u00ae Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","amount":"$1,326 million","upfrontCash":"$126.0 million","newsHeadline":"Omeros Completes Sale of OMIDRIA\u00ae Franchise to Rayner Surgical","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Neumentum","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuance Pharma Announces the Completion of Dosing for All NTM-001 Phase 1 Clinical Study Participants in HKU Clinical Trials Centre","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000929
Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (“NSAID”) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment.
Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.
The company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials with CA-008 (vocacapsaicin).
URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin’s benefit to patient recovery and rehabilitation.
Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.
As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force. Rayner plans to expand the sales force in both the U.S. and ex-U.S., and further accelerating U.S. market growth of OMIDRIA.
As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations. 
